Eevia Board Recommends Voluntary Liquidation
The Board of Directors of Eevia Health Plc (“Eevia” or the “Company”) has resolved to propose to the General Meeting of Shareholders that the Company enter voluntary liquidation. Despite a recent surge in commercial opportunities including new multi-million item orders and the initiation of supplier set-up with two of the world’s largest brands, the Board’s proposal is driven by the immediate liquidity challenges and overdue liabilities that the Company is unable to cover within a reasonable time, combined with the lack of access to new financing (both equity and non-dilutive).
Despite receiving sales order requests from customers exceeding EUR 2,5 million only in the last few weeks and ongoing sales processes with global blue-chip brands on new sales contracts for 2026, the Company’s current financial position prevents execution of these opportunities. Ongoing out-of-court restructuring measures, including a planned relocation of production to a “pay-for-time-used” facility, aimed at reducing fixed costs, are stalling due to a lack of short-term liquidity.
The Company will sell tangible assets (equipment) redundant due to the planned move of production, but it is uncertain if such a sale of assets would provide enough liquidity to enable both continuation of business and covering due liabilities. Furthermore, the Auditors continued questioning of the asset values despite significant write-downs already accepted, brings the question of solvency further to the forefront.
Management will continue to explore alternative solutions, including potential equity injections, bridge financing, and strategic collaborations, which could still provide a basis for continued operations if realized in the near term. The Board is formally recommending voluntary liquidation to ensure transparency and to safeguard the interests of creditors and will continuously evaluate other requirements under the Finnish Companies Act (Osakeyhtiölaki). However, it remains attentive to emerging opportunities and stands ready to reassess should concrete solutions materialize in the coming weeks that would be in the best interests of both creditors and shareholders.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: [email protected] or [email protected]
Telephone: +358 400 22 5967
This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was initially submitted for publication through the contact person's agency on August 22, 2025, at 10:30 CET.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc is a health ingredient company specialized in sustainable bioactive extracts from wild-harvested Nordic plants and berries. With a focus on gut health, kidney, and urinary health, as well as cellular protection, and inflammation, Eevia offers clinically relevant ingredients to global nutraceutical brands.
Eevia Health, founded in 2017, is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.